000042104 000__ 01480cam\a22002535i\4500
000042104 001__ 42104
000042104 003__ SzGeWIPO
000042104 005__ 20240708145900.0
000042104 008__ 200625s2020\\\\sz\\\\\\r\\\\\000\0\eng\d
000042104 040__ $$aSzGeWIPO$$beng$$erda
000042104 041__ $$aeng
000042104 1001_ $$aPila, Justine
000042104 24503 $$aReflections on a Post-Pandemic European Patent System
000042104 264_1 $$a[Toronto, Ontario] :$$b[Thomson Reuters],$$c2020.
000042104 300__ $$a19 pages
000042104 336__ $$atext$$btxt$$2rdacontent
000042104 337__ $$aunmediated$$bn$$2rdamedia
000042104 338__ $$avolume$$bnc$$2rdacarrier
000042104 520__ $$aAgainst the backdrop of COVID-19, this Opinion essay proposes three ways to improve the European patent system without the need for legislative reform. Each has particular implications for drug patenting, and reflects an interpretive conception of law and legal legitimacy as requiring the application of legislation in accordance with moral values, including those expressed in constitutional instruments. If adopted, the proposals would: restrict the patentability of second medical indications and anchor assessments of inventive step more firmly to patent policy; expand assessments of the moral and public policy implications of patenting inventions and extend the disclosure duties of applicants; and adapt the FRAND licensing system to cover essential medical technologies.
000042104 525__ $$aPublished in : European Intellectual Property Review
000042104 605_0 $$aPatents
000042104 650__ $$aInventive step
000042104 650_0 $$aFRAND licensing
000042104 650_0 $$aEssential medicines
000042104 650_0 $$aMorality
000042104 650_0 $$aPublic policy
000042104 650_0 $$aCOVID-19
000042104 650_0 $$aDrug patenting
000042104 85641 $$uhttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=3627384$$yView this resource
000042104 904__ $$aJournal article
000042104 980__ $$aBIB